Intranasal administration of the GHRP hexarelin accelerates growth in short children

Clin Endocrinol (Oxf). 1995 Nov;43(5):631-5. doi: 10.1111/j.1365-2265.1995.tb02929.x.

Abstract

Objective: Hexarelin is a recently synthesized small growth hormone releasing peptide (GHRP) (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys- NH2). It is active by intravenous, oral and intranasal administration in animals and man. The aim of this study was to find out whether long-term administration of this peptide would promote growth in short children.

Design and patients: Intranasal hexarelin was administered in a dose of 60 micrograms/kg thrice daily to 8 prepubertal short children aged 4-11.6 years for periods of up to 8 months.

Results: Hexarelin treatment stimulated insulin-like growth factor-I (IGF-I) secretion raising the level from 10.4 +/- 3.9 (SD) to 14.1 +/- 4.6 nmol/l (P < 0.004). The rise in IGF-I led to a significant increase in the mean (+/- SD) linear growth velocity from 5.3 +/- 0.8 to 8.3 +/- 1.7 cm/year (P < 0.0001). There was also a significant decrease in skinfold thickness despite increase in body weight and an increase in head circumference. Additional findings were a rise in serum phosphate from 1.5 +/- 0.1 to 1.8 +/- 0.1 mmol/l (P < 0.004) and of alkaline phosphatase from 219 +/- 74 to 261 +/- 75 U/l (P < 0.05).

Conclusions: The long-term GH/IGF-I stimulating, anabolic and growth promoting effects achieved by intranasal administration of this hexapeptide, seemingly without undesirable side-effects, suggests clinical potential for this new class of drugs.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Alkaline Phosphatase / blood
  • Body Weight / drug effects
  • Cephalometry
  • Child
  • Child, Preschool
  • Drug Administration Schedule
  • Female
  • Growth Disorders / blood
  • Growth Disorders / drug therapy*
  • Growth Substances / administration & dosage*
  • Growth Substances / therapeutic use
  • Hormones / administration & dosage
  • Hormones / therapeutic use
  • Humans
  • Insulin-Like Growth Factor I / metabolism
  • Male
  • Oligopeptides / administration & dosage*
  • Oligopeptides / therapeutic use
  • Phosphates / blood
  • Skinfold Thickness
  • Stimulation, Chemical

Substances

  • Growth Substances
  • Hormones
  • Oligopeptides
  • Phosphates
  • hexarelin
  • Insulin-Like Growth Factor I
  • Alkaline Phosphatase